Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial

Journal of Bone and Mineral Research

Volumn 25, Issue 10, 2010, Pages 2251-2255

  Grey, Andrew ^a   Bolland, Mark ^a   Wattie, Diana ^a   Horne, Anne ^a   Gamble, Greg ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antiresorptive; Bone density; Bone turnover; Osteoporosis therapy; Zoledronate

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; COLLAGEN TYPE 1; ESTRADIOL; PLACEBO; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; EYE INFLAMMATION; FEMALE; HEART ATRIUM FIBRILLATION; HIP; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LUMBAR SPINE; OSTEOPENIA; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE;

EID: 77954287599     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.103     Document Type: Article

References (11)

1. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
2. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
3. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661. (Pubitemid 34815869)
4. Bolland M, Grey A, Horne A, et al. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res. 2008;23:1304-1308.
5. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C-L. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized, controlled trial. Obstet Gynecol. 2009;114:999-1007.
6. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009;94:538-544.
7. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008;42:623-630.
8. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
9. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19:1250-1258.
10. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet. 2006;368:973-974.
11. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711-719. (Pubitemid 46684777)